Inovio Pharmaceuticals, Inc.
NASDAQ:INO · NASDAQ Global Select
-$0.01 today
Vol 2.50M · Avg 2.73M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-352.5%
avg -417.0%
ROIC
-259.4%
avg -93.0%
ROA
-114.3%
avg -65.5%
Analysis
ROA is currently the strongest return metric at -114.3% versus its period average of -65.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jacqueline E. Shea | Chief Executive Officer, President & Director | $889,099.00 | — | 60 | $123,760.00 | 0.23% |
Laurent Humeau | Chief Scientific Officer & Chairman of the Scientific Advisory Board | $794,082.00 | — | 59 | $48,986.00 | 0.09% |
Michael Sumner | Chief Medical Officer & Head of Development | $653,475.00 | — | 61 | $46,876.00 | 0.09% |
Peter D. Kies | Chief Financial Officer | $598,278.00 | — | 63 | $47,542.00 | 0.09% |
Jeffrey Skolnik | Senior Vice President of Clinical Development | — | — | — | — | — |
E. J. Brandreth | Senior Vice President of Quality Assurance | — | — | — | — | — |
Robert J. Juba Jr. | Senior Vice President of Biological Manufacturing & Clinical Supply Management | — | — | — | — | — |
Robert L. Crotty | General Counsel, Corporate Secretary & Chief Compliance Officer | — | — | 52 | — | — |
Shawn D. Bridy | Senior Vice President of Business Development | — | — | — | — | — |
Jennie Willson | Director of Communications | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +114.4% | +12.3% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +114.4% over three years. Forward estimates point to Revenue at +12.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Opus Genetics, Inc.
NASDAQ:IRD
$338.48M
Fate Therapeutics, Inc.
NASDAQ:FATE
$235.45M
Alector, Inc.
NASDAQ:ALEC
$184.86M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$139.22M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$128.83M
Agenus Inc.
NASDAQ:AGEN
$123.03M
Seer, Inc.
NASDAQ:SEER
$94.57M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$63.53M
Actuate Therapeutics Inc
NASDAQ:ACTU
$50.01M
VistaGen Therapeutics, Inc.
VTGN
$22.62M
Who manages INO?
Inovio Pharmaceuticals, Inc. (INO) lists 10 active executives. The top listed executive is Jeffrey Skolnik, Senior Vice President of Clinical Development.
Are INO insiders buying or selling?
Recent insider activity shows net buying of $1.81M.
Explore More
Continue the stock analysis
Jump to another research area for this company.